CDKL1

Cyclin-dependent kinase-like 1

253 patent compounds predicted against CDKL1, 225 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL4513682	1.00	1/20
SCHEMBL2922722	0.81	1/20
SCHEMBL2920438	0.81	1/20
SCHEMBL2922723	0.80	1/20
SCHEMBL2929124	0.80	1/20
SCHEMBL2921519	0.76	1/20
SCHEMBL2924297	0.73	1/20
SCHEMBL4521927	0.73	1/20
SCHEMBL1447609	0.73	1/20
SCHEMBL1447688	0.72	1/20
SCHEMBL4245312	0.69	1/20
SCHEMBL1447917	0.69	1/20
SCHEMBL1447436	0.68	1/20
SCHEMBL3551552	0.66	1/20
SCHEMBL1448381	0.66	1/20
SCHEMBL274821	0.65	1/20
SCHEMBL278928	0.64	1/20
SCHEMBL1447533	0.63	1/20
SCHEMBL273247	0.63	1/20
SCHEMBL2924704	0.63	1/20

Germline variants in CDKL1 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full CDKL1 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to CDKL1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt	PHASE4	COMPLETED
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)	PHASE3	COMPLETED
Double-blind, Randomized, Placebo-controlled Trial of Ganaxolone in CDKL5 Deficiency Patients 6 Months to Less Than 2 Years Old	PHASE3	NOT_YET_RECRUITING
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer	PHASE3	ACTIVE_NOT_RECRUITING
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression	PHASE2	COMPLETED
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6	PHASE2	RECRUITING
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)	PHASE1/PHASE2	RECRUITING
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer	PHASE2	ACTIVE_NOT_RECRUITING
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer	PHASE2	UNKNOWN
Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma	PHASE1/PHASE2	RECRUITING
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer	PHASE2	COMPLETED
Avelumab, Palbociclib and Axitinib in Advanced RCC	PHASE2	WITHDRAWN
A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors	PHASE1/PHASE2	COMPLETED
Histology-Independent Study of Palbociclib in Patients With Advanced Cancer	PHASE2	WITHDRAWN
Abemaciclib + Pembrolizumab In Glioblastoma	PHASE2	WITHDRAWN
Palbociclib With Everolimus + Exemestane In BC	PHASE1/PHASE2	COMPLETED
An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.	PHASE1/PHASE2	COMPLETED
Genetic Testing in Guiding Treatment for Patients With Brain Metastases	PHASE2	ACTIVE_NOT_RECRUITING
Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC	PHASE2	ACTIVE_NOT_RECRUITING
To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy	PHASE2	COMPLETED
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer	PHASE2	RECRUITING
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies	PHASE1	RECRUITING
Study of FCN-437c in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms	PHASE1	COMPLETED
Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma	PHASE1	COMPLETED
AZD1775 for Advanced Solid Tumors	PHASE1	COMPLETED
TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy	PHASE1	RECRUITING
A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers	PHASE1	COMPLETED
Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period	nan	UNKNOWN
The SONImage Study	nan	ACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a CDKL1 binder may also engage these)

Protein	Name	Similarity
Q8CEQ0	—	1.000	Q8CEQ0 →
Q66HE7	—	1.000	Q66HE7 →
Q6AXJ9	—	1.000	Q6AXJ9 →
Q3TZA2	—	0.999	Q3TZA2 →
CDKL4	Cyclin-dependent kinase-like 4	0.993	landscape →
Q8VZD5	—	0.993	Q8VZD5 →
Q9U2Q9	—	0.992	Q9U2Q9 →
P51138	—	0.992	P51138 →
P43289	—	0.991	P43289 →
Q9FVS6	—	0.991	Q9FVS6 →
P43288	—	0.991	P43288 →
Q40518	—	0.990	Q40518 →
Q9U2H1	—	0.989	Q9U2H1 →
P51137	—	0.989	P51137 →
P43294	—	0.989	P43294 →
O44408	—	0.989	O44408 →
Q12126	—	0.989	Q12126 →
Q8MXI4	—	0.989	Q8MXI4 →
Q8SR90	—	0.988	Q8SR90 →
A8WIP6	—	0.988	A8WIP6 →
Q755C4	—	0.988	Q755C4 →
P21965	—	0.988	P21965 →
Q39011	—	0.988	Q39011 →
Q3S406	—	0.987	Q3S406 →
Q9URT9	—	0.987	Q9URT9 →
A8X5H5	—	0.987	A8X5H5 →
O35832	—	0.987	O35832 →
Q384J7	—	0.987	Q384J7 →
G5EFV5	—	0.987	G5EFV5 →
G4NH08	—	0.986	G4NH08 →